SMAD4 and non-small cell lung carcinoma: Additionally, this drug combination reduces the expression levels of HIF1α and VEGF, inhibits tumor angiogenesis, and limits blood supply to tumor tissues, ultimately leading to tumor cell apoptosis and significantly enhancing the therapeutic effect against lung cancer.[39] Zhang et al.’s research demonstrates that enhancer of Zeste homolog 2 (EZH2) and euchromatic histone lysine methyltransferase 2 (EHMT2) act synergistically in non‐small cell lung cancer (NSCLC), with their interaction leading to the silencing of the tumor suppressor gene mothers against decapentaplegic homolog 4 (SMAD4).